VSIR and mesothelioma: The trials on new immune checkpoint targets such as anti-VISTA, OX40, LAG-3, and TIM-3 are all in their infancy, with data coming from basket trials or ongoing phase 1 trials, thus more data on mesothelioma patients specifically are needed.